And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, as you know, our treasured signal to daydream about weekend plans. And our agenda is actually rather modest. We hope to catch up on some work (yes, it never stops) and some reading, as well as take a nap or three. And what about you? This may be an opportunity to hit the pause button on the dizzying political developments and enjoy a football match. You could make time to reach out to someone special. Or if you feel brave, you could plan the rest of your life. Well, whatever you do, have a grand time, but be safe. Enjoy, and see you soon …
Biogen received a subpoena in December from federal investigators about government price reporting, rebate payments, and co-pay assistance programs for four drugs, according to a filing with the US Securities and Exchange Commission. The biotech also received a civil investigative demand for documents and information about relationships with entities providing clinical education and reimbursement support services.
About the Author Reprints
With all due difidence to Mr Meeker, since he is speaking US English, ‘trust us’ that is precisely what he is saying. Industry innovation and rapacity are not mutually dependent, but neither are extreme bonuses nor huge stock buybacks. Well, they are if you leave out ‘innovation.’